• Other

    Other
  • CN

    CN
  • EU

    EU
  • USA

    USA
    • My cart
    In the shopping cart is not goods, to choose and buy!
    • Product Name
    • Size
    • Quantity
    • Amount
      Selected items : 0 pieces Total : CHECK OUT()
      Olanzapine (LY170053)
      Olanzapine (LY170053)

      Price：
      Market Price：

      This product is for research use only, not for human use. We do not sell to patients.
      Number： - + Pieces（InventoryPieces）
      InvivoChem Cat #: V0963
      CAS #: 132539-06-1 Purity ≥98%

      Description: Olanzapine (formerly LY-170052, LY 170052, Zyprexa, Zolafren), a thienobenzodiazepine analog, is an approved and atypical antipsychotic drug with high affinity for 5-HT2 serotonin and D2 dopamine receptor antagonist. It is a dopamine antagonist and is classified as a thienobenzodiazepine. Binding studies showed that olanzapine interacted with keyreceptorsof interest in schizophrenia, exihibiting a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscarinic receptors. It is approved by the U.S. FDA for the treatment of schizophrenia and bipolar disorder. Olanzapine is structurally similar to clozapine and quetiapine.

      References: J Clin Psychiatry. 1997;58 Suppl 10:28-36; Neuropsychopharmacology. 2000 Sep;23(3):250-62.

      Related CAS#: 174794-02-6 (Olanzapine N-Oxide)

      Customer Validation
      Official Supplier of
      • VE
      • OF
      • YALE
      • hhmi
      • 香港大学
      Related Products
      Publications Citing InvivoChem Products
      • Physicochemical and Storage Information
      • Protocol
      • Quality Control Documentation
      • Related Biological Data
      • Customer Review
      Molecular Weight (MW)312.44
      FormulaC17H20N4S
      CAS No.132539-06-1
      Storage-20℃ for 3 years in powder form
      -80℃ for 2 years in solvent
      Solubility (In vitro)DMSO: 63 mg/mL (201.6 mM)
      Water: <1 mg/mL
      Ethanol: 9 mg/mL (28.8 mM)
      SMILES CodeCN1CCN(C2=C(C=C(C)S3)C3=NC4=CC=CC=C4N2)CC1
      SynonymsLY170053; LY-170052, Olanzapine, LY 170052, Zyprexa, Zolafren


      • Molarity Calculator
      • Dilution Calculator
      • The molarity calculator equation

        Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

        • Mass
        • Concentration
        • Volume
        • Molecular Weight *
        • =
        • ×
        • ×
      • The dilution calculator equation

        Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

        This equation is commonly abbreviated as: C1V1 = C2V2

        • Concentration (start)
        • ×
        • Volume (start)
        • =
        • Concentration (final)
        • ×
        • Volume (final)
        • ×
        • =
        • ×
        • C1
        •  
        • V1
        •  
        • C2
        •  
        • V2
      In Vitro

      In vitro activity: Olanzapine interacts with key receptors of interest in schizophrenia, having a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscarinic receptors. Olanzapine has a receptor profile that is similar to that of clozapine: it is relatively nonselective at dopamine receptor subtypes and it shows selectivity for mesolimbic and mesocortical over striatal dopamine tracts (electrophysiology; Fos).  

      In VivoOlanzapine is a potent antagonist at DA receptors (DOPAC levels; pergolide-stimulated increases in plasma corticosterone) and 5-HT receptors (quipazine-stimulated increases in corticosterone), but is weaker at alpha-adrenergic and muscarinic receptors. Olanzapine combined with fluoxetine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline in rat prefrontal cortex, respectively, which are significantly greater than either drug alone. Olanzapine at 0.5 mg/kg, 3 mg/kg and 10 mg/kg (s.c.) dose-dependently increases the extracellular dopamine (DA) and norepinephrine (NE) levels in rat prefrontal cortex, nucleus accumbens and striatum. Olanzapine also increases extracellular levels of a DA metabolite, DOPAC, and tissue concentrations of a released DA metabolite, 3-methoxytyramine. Olanzapine results in an 8-11% reduction in mean fresh brain weights as well as left cerebrum fresh weights and volumes in macaque monkeys. Olanzapine results in substantial increases in adiposity: increased total body fat reflecting marked increases in subcutaneous and visceral adipose stores. Olanzapine results in marked hepatic insulin resistance.
      Animal modelMacaque monkeys
      Formulation & Dosage0.5 mg/kg, 3 mg/kg and 10 mg/kg (s.c.)
      ReferencesJ Clin Psychiatry. 1997;58 Suppl 10:28-36; Neuropsychopharmacology. 2000 Sep;23(3):250-62.

      These protocols are for reference only. InvivoChem does not independently validate these methods.

      评论

        Home Prev Next Last page / pices

        发评论

        ×
        Your information is safe with us. * Required Fields.
        Products are for research use only;  We do not sell to patients
        Contact Us
        Contact Us
        Tel: 1-708-310-1919
        Fax: 1-708-557-7486
        Email: [email protected]
        Frequently Asked Questions
        Subscribe to our E-newsletter
        • Name*
        • *
        • E-mail*
        • *
        • instructions：
        • *
        Copyright 2020 InvivoChem LLC | All Rights Reserved
          Site map
        prompt
        Do you confirm the receipt?